News
ALZ-101 enters Phase II start-up as Alzinova raises capital
Maria Karlsson Osipova
2026-09-11
10:14 CEST
Alzinova has initiated operational preparations for the global Phase II study of ALZ-101, and also announced a SEK51m rights issue to fund the next stage.
Last night, Alzinova announced the operational start-up of its global Phase II study of ALZ-101 with Worldwide Clinical Trials. Regulatory and ethics submissions, site selection and trial-system set-up are now under way, and the company targets first patient enrolment around YE 2026. The planned study will enrol c120 patients with early Alzheimer’s disease, with the change in cognitive performance measured by ADCOMS at 52 weeks as the primary endpoint, and total follow-up of 92 weeks. Later the same evening, the company announced a SEK51m rights issue, c79% covered by subscription and underwriting commitments. Net proceeds of cSEK42m, assuming full subscription and cash underwriting compensation, will mainly fund Phase II execution and CMC activities. The units also include TO5 and TO6 warrants, which could provide up to SEK203m in additional proceeds during 2027. The subscription period runs from 22 September to 6 October, at a subscription price of SEK0.42 per share.
Our view. We view the operational start-up positively, as it makes the Phase II plan more tangible and provides a timeline for first-patient enrolment. Our prior understanding was that a Phase II study could involve roughly 80 patients per arm (c160 patients in total) with a study duration of around 80 weeks. The press release now confirms a placebo-controlled design and broadly similar overall follow-up of 92 weeks, but with c120 patients in total and change in ADCOMS at 52 weeks as the primary endpoint. The final study therefore appears somewhat smaller than we had anticipated, although other key design details remain undisclosed. As for the financing, we view it as a necessary step to advance the programme, and broadly in line with our previous assumption that external capital would be required absent a partnership. We will return with an updated share count, estimates and valuation once the final outcome of the rights issue and the terms of the warrants are reflected in our model.